Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke
Open Access
- 11 December 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 8 (1), 1-10
- https://doi.org/10.1038/s41598-018-35898-z
Abstract
Although the regulation of post-ischemic inflammation is an important strategy to treat ischemic stroke, all clinical trials have failed to show its efficacy. To solve the problem, we previously developed a novel partial peptide of RANKL, microglial healing peptide 1 (MHP1), which could reduce ischemic injury by inhibiting Toll-like receptor (TLR) induced inflammation. However, optimization of the peptide was necessary to increase the stability and efficacies for clinical use. According to information gathered through HPLC/MS in serum, we have newly designed a series of modified MHP1 peptides and have found that N-terminal acetylation and C-terminal amidation in MHP1 (MHP1-AcN), can strengthen its anti-inflammatory effects and increase its stability with anti-osteoclastogenic effects. Anti-TLR activity was reported to be reduced in MHP1 when incubated at 37 °C for 24 hrs, but MHP1-AcN could keep the activity under the same condition. The therapeutic effect of MHP1-AcN was observed in transient ischemic stroke model at lower dose than MHP1. Importantly, MHP1-AcN did not affect thrombolytic effects of tissue plasminogen activator (tPA) and inhibited tPA-induced hemorrhagic transformation. These findings indicated that MHP1-AcN was stable and effective anti-TLR signal peptide and could be a promising agent for treating stroke patients receiving tPA and endovascular therapy.This publication has 27 references indexed in Scilit:
- SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke)Stroke, 2018
- Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective TherapiesStroke, 2011
- The immunology of stroke: from mechanisms to translationNature Medicine, 2011
- Toll-like receptors 7 and 8 expression is associated with poor outcome and greater inflammatory response in acute ischemic strokeClinical Immunology, 2011
- Do RANKL inhibitors (denosumab) affect inflammation and immunity?Osteoporosis International, 2010
- Update of the Stroke Therapy Academic Industry Roundtable Preclinical RecommendationsStroke, 2009
- Activation of TLR4-Mediated NFB Signaling in Hemorrhagic Brain in RatsMediators of Inflammation, 2009
- Suppressive effect of simvastatin on interferon-β-induced expression of CC chemokine ligand 5 in microgliaNeuroscience Letters, 2006
- Partial d -amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptideProceedings of the National Academy of Sciences of the United States of America, 2005
- Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's DiseaseOnline Journal of Public Health Informatics, 2003